1. Home
  2. SPRO vs INO Comparison

SPRO vs INO Comparison

Compare SPRO & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

HOLD

Current Price

$1.60

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
INO
Founded
2013
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
114.0M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
SPRO
INO
Price
$2.34
$1.60
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$6.75
AVG Volume (30 Days)
251.4K
624.8K
Earning Date
03-26-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
54.18
EPS
0.15
N/A
Revenue
$66,802,000.00
$42,220,086.00
Revenue This Year
N/A
$24,407.60
Revenue Next Year
N/A
$331.40
P/E Ratio
N/A
N/A
Revenue Growth
39.24
19.37
52 Week Low
$0.51
$1.30
52 Week High
$3.09
$2.86

Technical Indicators

Market Signals
Indicator
SPRO
INO
Relative Strength Index (RSI) 44.87 44.05
Support Level $2.31 $1.48
Resistance Level $2.44 $1.78
Average True Range (ATR) 0.12 0.08
MACD -0.02 -0.01
Stochastic Oscillator 11.90 35.19

Price Performance

Historical Comparison
SPRO
INO

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Share on Social Networks: